Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy ATLANTA, GA - (NEWMEDIAWIRE) - GeoVax Labs, ...

GeoVax Labs (GOVX) announced significant progress in advancing Gedeptin as a cancer therapy. Gedeptin, based on a Gene-Directed Enzyme Prodrug ...

Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among ...

GeoVax Labs Inc (NASDAQ:GOVX) shares are trading lower Tuesday, pulling back from recent strength after the company announced an offering of 1.7 million shares at a price of $5 per share.

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have been assigned an average rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. Five ...

Alliance Global Partners has recently initiated Geovax Labs Inc (GOVX) stock to Buy rating, as announced on November 11, 2024, according to Finviz. Earlier, on July 16, 2024, ROTH MKM had initiated ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial 15.01.2025 / 15:05 CET/CEST The issuer is solely responsible for the content ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...